Phase 3 Clinical Trials With Primary Completion Dates in March 2023

This is a list of Phase 3 trials with primary completion dates in March 2023 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

SymbolCompanyPrimary Completion DatePhaseNCT IDTitle
ACADACADIA Pharmaceuticals Inc.2023-03-01Phase 3NCT04531982Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia
ALLKAllakos Inc.2023-03-01Phase 3NCT04620811An Extension Study of Lirentelimab in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)
CINGCingulate Inc.2023-03-01Phase 3NCT05631626Phase 3 Efficacy and Safety Study in Adults With ADHD Using CTx-1301.
EBSEmergent BioSolutions Inc.2023-03-01Phase 3NCT05072080A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317
KODKodiak Sciences Inc.2023-03-01Phase 3NCT04964089A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)
KPTIKaryopharm Therapeutics Inc.2023-03-01Phase 3NCT03555422Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]
OPHLYOno Pharmaceutical Co., Ltd.2023-03-01Phase 3NCT03006705Study of Adjuvant ONO-4538 With Resected Gastric Cancer
PYPDPolyPid Ltd.2023-03-01Phase 3NCT04411199D-PLEX 312 - Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection (SHIELD II)